Rentschler Biopharma, looking to focus on biologics, has unveiled a global realignment, withdrawing from the field of cell and gene therapy and ceasing operations at its Stevenage, UK site.
According to Rentschler, “slower-than-expected growth” in the cell and gene therapy market has led to “demand across the industry not meeting our expectations.” Following its comprehensive strategic review, the CDMO plans to focus efforts on “areas where we see the greatest demand and potential to create value sustainably.”
Rentschler forayed into the CGT space in 2021, purchasing its Stevenage site from the Cell and Gene Therapy Catapult that had originally been set up as an independent center of excellence in the UK. Rentschler invested into the site, adding CGMP lentiviral vector manufacturing capabilities to the existing AAV offerings.
Rentschler is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with a second facility in Milford, Massachusetts.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!